Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS)
Fiscal 2024 First Quarter

(January 1, 2024 - March 31, 2024)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on May 7, 2024 for the first three months of Fiscal 2024, from January 1, 2024 to March 31, 2024.
- This document is an English translation of the Japanese-language original.
- The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth
- Figures inside parenthesis presented in these materials indicate negative values.
- Change amount in these materials presents change amount compared to the same period of the previous fiscal year.
I. Consolidated Financial Results
   1. Trends in consolidated profit 1
   2. Revenue by regional control function 2
   3. Revenue by location of customer 2
   4. Capital expenditures and intangible assets investment, depreciation and amortization 2
   5. Number of employees by regional control function 2

II. Consolidated Statement of Cash Flows 2

III. Revenue from Main Products 3

IV. R&D Pipeline 6

The average exchange rates for each period were as follows:

<table>
<thead>
<tr>
<th>Unit: Yen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>USD</td>
<td>132</td>
<td>134</td>
<td>137</td>
</tr>
<tr>
<td>GBP</td>
<td>161</td>
<td>164</td>
<td>170</td>
</tr>
<tr>
<td>EUR</td>
<td>141</td>
<td>144</td>
<td>148</td>
</tr>
</tbody>
</table>

Contact
Kyowa Kirin Co., Ltd.
Corporate Communications Department
Tel +81 3 5205 7206
### I. Consolidated Financial Results

#### 1. Trends in consolidated profit

**<Accumulative>**

The “★” symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.

<table>
<thead>
<tr>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>93.5</td>
<td>159.2</td>
<td>306.1</td>
</tr>
<tr>
<td># CAGR (compared to FY 2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(18.9)</td>
<td>(47.0)</td>
<td>(77.0)</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74.6</td>
<td>152.2</td>
<td>229.1</td>
</tr>
<tr>
<td>Gross profit to revenue ratio</td>
<td>79.7%</td>
<td>76.4%</td>
</tr>
<tr>
<td><strong>Selling, general and administrative expenses</strong></td>
<td>(41.8)</td>
<td>(82.4)</td>
</tr>
<tr>
<td><strong>Research and development expenses</strong></td>
<td>(16.6)</td>
<td>(33.7)</td>
</tr>
<tr>
<td>★ R&amp;D expense ratio</td>
<td>17.8%</td>
<td>19.9%</td>
</tr>
<tr>
<td>Share of profit (loss) of investments accounted for using equity method</td>
<td>0.8</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>Core operating profit</strong></td>
<td>17.0</td>
<td>37.5</td>
</tr>
<tr>
<td># Core operating profit ratio</td>
<td>18.2%</td>
<td>18.8%</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td>0.2</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td>(2.6)</td>
<td>(14.2)</td>
</tr>
<tr>
<td>Finance income (costs)</td>
<td>1.0</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Profit before tax</strong></td>
<td>15.6</td>
<td>26.0</td>
</tr>
<tr>
<td><strong>Income tax expense</strong></td>
<td>(2.8)</td>
<td>(4.4)</td>
</tr>
<tr>
<td><strong>Profit</strong></td>
<td>12.8</td>
<td>21.6</td>
</tr>
<tr>
<td><strong>Profit to revenue ratio</strong></td>
<td>13.6%</td>
<td>19.9%</td>
</tr>
<tr>
<td><strong>EPS ($/share)</strong></td>
<td>23.74</td>
<td>40.27</td>
</tr>
<tr>
<td><strong>Core EPS ($/share)</strong></td>
<td>27.33</td>
<td>61.40</td>
</tr>
<tr>
<td><strong>Annual dividend ($/share)</strong></td>
<td>56.00</td>
<td>58.00</td>
</tr>
<tr>
<td><strong>Dividend payout ratio (%)</strong></td>
<td>35.5%</td>
<td>47.6</td>
</tr>
<tr>
<td><strong>ROE (%)</strong></td>
<td>10.2</td>
<td>7.6</td>
</tr>
</tbody>
</table>

Notes:
- *Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting “other income,” “other expenses” and the related “income tax expense” from “profit”) by the average number of shares during the period.*
- *Dividend payout ratio is shown based on core EPS.*

**<Quarterly>**

<table>
<thead>
<tr>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>Jan - Mar</td>
<td>Apr - Jun</td>
</tr>
<tr>
<td>93.5</td>
<td>105.7</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(18.9)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>74.6</td>
</tr>
<tr>
<td>Gross profit to revenue ratio</td>
<td>79.7%</td>
</tr>
<tr>
<td>Selling, general and administrative expenses</td>
<td>(41.8)</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>(16.6)</td>
</tr>
<tr>
<td>★ R&amp;D expense ratio</td>
<td>17.8%</td>
</tr>
<tr>
<td>Share of profit (loss) of investments accounted for using equity method</td>
<td>0.8</td>
</tr>
<tr>
<td>Core operating profit</td>
<td>17.0</td>
</tr>
<tr>
<td># Core operating profit ratio</td>
<td>18.2%</td>
</tr>
<tr>
<td>Other income</td>
<td>0.2</td>
</tr>
<tr>
<td>Other expenses</td>
<td>(2.6)</td>
</tr>
<tr>
<td>Finance income (costs)</td>
<td>1.0</td>
</tr>
<tr>
<td>Profit before tax</td>
<td>15.6</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>(2.8)</td>
</tr>
<tr>
<td>Profit</td>
<td>12.8</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>13.6%</td>
</tr>
</tbody>
</table>
### 2. Revenue by regional control function

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Japan</td>
<td>34.0</td>
<td>70.9</td>
<td>107.0</td>
</tr>
<tr>
<td>North America</td>
<td>25.7</td>
<td>60.3</td>
<td>92.9</td>
</tr>
<tr>
<td>EMEA</td>
<td>15.4</td>
<td>30.8</td>
<td>45.7</td>
</tr>
<tr>
<td>APAC</td>
<td>7.4</td>
<td>16.0</td>
<td>26.0</td>
</tr>
<tr>
<td>Others</td>
<td>11.0</td>
<td>21.2</td>
<td>34.5</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>93.5</td>
<td>199.2</td>
<td>306.1</td>
</tr>
</tbody>
</table>

*Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization based on four regions of Japan, North America, EMEA and APAC, a functional organization, and a product organization (product franchises).

**EMEA consists of Europe, the Middle East, Africa, etc.**

**Others consists of revenue from technology out-licensing, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics plc), original equipment manufacturer.**

### 3. Revenue by location of customer

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Japan</td>
<td>35.0</td>
<td>73.7</td>
<td>111.1</td>
</tr>
<tr>
<td>International</td>
<td>58.5</td>
<td>125.6</td>
<td>194.9</td>
</tr>
<tr>
<td>Americas</td>
<td>34.2</td>
<td>76.9</td>
<td>121.5</td>
</tr>
<tr>
<td>Of which, the U.S.</td>
<td>32.8</td>
<td>74.4</td>
<td>117.7</td>
</tr>
<tr>
<td>Europe</td>
<td>14.4</td>
<td>28.5</td>
<td>40.9</td>
</tr>
<tr>
<td>Asia</td>
<td>9.7</td>
<td>19.8</td>
<td>31.9</td>
</tr>
<tr>
<td>Others</td>
<td>0.2</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>93.5</td>
<td>199.2</td>
<td>306.1</td>
</tr>
</tbody>
</table>

*Revenue by location of customer is classified by region or country based on location of customer.

### 4. Capital expenditures and intangible assets investment, depreciation and amortization

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Capital expenditures (property, plant and equipment)*</td>
<td>3.7</td>
<td>7.0</td>
<td>10.5</td>
</tr>
<tr>
<td>Intangible assets investment</td>
<td>2.3</td>
<td>4.7</td>
<td>13.6</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>6.0</td>
<td>11.7</td>
<td>24.1</td>
</tr>
<tr>
<td>Depreciation (property, plant and equipment)</td>
<td>3.1</td>
<td>6.3</td>
<td>9.7</td>
</tr>
<tr>
<td>Amortization (intangible assets)</td>
<td>1.8</td>
<td>3.6</td>
<td>5.8</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>4.8</td>
<td>9.9</td>
<td>15.5</td>
</tr>
</tbody>
</table>

*Acquisitions of right-of-use assets are not included.

### 5. Number of employees by regional control function

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As of March 31</td>
<td>As of June 30</td>
</tr>
<tr>
<td></td>
<td>As of September 30</td>
<td>As of December 31</td>
</tr>
<tr>
<td>Japan</td>
<td>4,154</td>
<td>4,236</td>
</tr>
<tr>
<td>North America</td>
<td>574</td>
<td>608</td>
</tr>
<tr>
<td>EMEA</td>
<td>743</td>
<td>714</td>
</tr>
<tr>
<td>APAC</td>
<td>571</td>
<td>578</td>
</tr>
<tr>
<td>Others</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>6,042</td>
<td>6,136</td>
</tr>
</tbody>
</table>

*Others consists of number of employees of Orchard Therapeutics plc.

### II. Consolidated Statement of Cash Flows

<table>
<thead>
<tr>
<th></th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
</tr>
<tr>
<td>Cash flows from operating activities</td>
<td>29.4</td>
<td>60.3</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td>(9.1)</td>
<td>(14.0)</td>
</tr>
<tr>
<td>Cash flows from financing activities</td>
<td>(15.2)</td>
<td>(16.1)</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash and cash equivalents</td>
<td>0.5</td>
<td>2.6</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents</td>
<td>5.7</td>
<td>32.9</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of period</td>
<td>339.2</td>
<td>339.2</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of period</td>
<td>344.8</td>
<td>372.1</td>
</tr>
</tbody>
</table>
### III. Revenue from Main Products

#### Unit: Billions of yen

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
<th>Change amount</th>
<th>Jan - Mar</th>
<th>Jan - Jun</th>
<th>Jan - Sep</th>
<th>Jan - Dec</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystiva</td>
<td>2.3</td>
<td>4.8</td>
<td>7.4</td>
<td>10.5</td>
<td>2.5</td>
<td>0.2</td>
<td>12.9</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>Potelleigo</td>
<td>0.4</td>
<td>0.9</td>
<td>1.4</td>
<td>1.9</td>
<td>0.4</td>
<td>0.0</td>
<td>1.9</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Nesp</td>
<td>0.8</td>
<td>1.5</td>
<td>2.3</td>
<td>3.2</td>
<td>0.7</td>
<td>(0.1)</td>
<td>2.8</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Darbepoetin Alfa Injection Syringe [KKF]</td>
<td>3.5</td>
<td>6.9</td>
<td>10.3</td>
<td>14.0</td>
<td>2.8</td>
<td>(0.7)</td>
<td>11.7</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Duvroq</td>
<td>1.8</td>
<td>4.2</td>
<td>6.9</td>
<td>9.9</td>
<td>2.5</td>
<td>0.7</td>
<td>12.2</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>PHOZEVEL</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.6</td>
<td>0.6</td>
<td>3.3</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>Regpara</td>
<td>0.4</td>
<td>0.8</td>
<td>1.2</td>
<td>1.7</td>
<td>0.3</td>
<td>(0.1)</td>
<td>0.9</td>
<td>32%</td>
<td></td>
</tr>
<tr>
<td>Orkedia</td>
<td>2.2</td>
<td>5.0</td>
<td>7.6</td>
<td>10.6</td>
<td>2.2</td>
<td>(0.1)</td>
<td>11.7</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>Rocaltrol</td>
<td>0.7</td>
<td>1.4</td>
<td>2.1</td>
<td>2.9</td>
<td>0.6</td>
<td>(0.1)</td>
<td>2.8</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td>Onglyza</td>
<td>1.1</td>
<td>2.2</td>
<td>3.2</td>
<td>4.3</td>
<td>0.8</td>
<td>(0.2)</td>
<td>3.0</td>
<td>28%</td>
<td></td>
</tr>
<tr>
<td>Coniel</td>
<td>0.4</td>
<td>0.7</td>
<td>1.1</td>
<td>1.5</td>
<td>0.3</td>
<td>(0.1)</td>
<td>1.2</td>
<td>26%</td>
<td></td>
</tr>
<tr>
<td>G-Lasta</td>
<td>7.0</td>
<td>15.0</td>
<td>23.2</td>
<td>31.9</td>
<td>5.8</td>
<td>(1.3)</td>
<td>20.5</td>
<td>28%</td>
<td></td>
</tr>
<tr>
<td>Fentos</td>
<td>0.7</td>
<td>1.6</td>
<td>2.5</td>
<td>3.5</td>
<td>0.7</td>
<td>(0.0)</td>
<td>3.0</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Rituiximab BS [KKH]</td>
<td>2.2</td>
<td>4.4</td>
<td>6.7</td>
<td>9.0</td>
<td>1.9</td>
<td>(0.3)</td>
<td>7.9</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Romiplate</td>
<td>2.7</td>
<td>5.7</td>
<td>8.7</td>
<td>12.0</td>
<td>3.0</td>
<td>0.3</td>
<td>13.2</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Allelock</td>
<td>1.9</td>
<td>3.1</td>
<td>4.1</td>
<td>5.5</td>
<td>1.7</td>
<td>(0.3)</td>
<td>3.6</td>
<td>47%</td>
<td></td>
</tr>
<tr>
<td>Patanol</td>
<td>1.4</td>
<td>1.5</td>
<td>1.7</td>
<td>2.0</td>
<td>0.8</td>
<td>(0.6)</td>
<td>1.3</td>
<td>63%</td>
<td></td>
</tr>
<tr>
<td>Dovobet</td>
<td>1.8</td>
<td>3.9</td>
<td>5.7</td>
<td>7.9</td>
<td>1.8</td>
<td>0.0</td>
<td>7.1</td>
<td>26%</td>
<td></td>
</tr>
<tr>
<td>Lumicef</td>
<td>0.6</td>
<td>1.3</td>
<td>2.1</td>
<td>2.8</td>
<td>0.6</td>
<td>(0.0)</td>
<td>2.6</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Nourianz</td>
<td>1.7</td>
<td>3.7</td>
<td>5.5</td>
<td>7.6</td>
<td>1.5</td>
<td>(0.2)</td>
<td>7.1</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td>HARUROPI</td>
<td>0.9</td>
<td>2.1</td>
<td>3.2</td>
<td>4.5</td>
<td>1.0</td>
<td>0.0</td>
<td>5.2</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>Depakene</td>
<td>0.6</td>
<td>1.4</td>
<td>2.1</td>
<td>2.8</td>
<td>0.6</td>
<td>(0.1)</td>
<td>2.4</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Crystiva</td>
<td>27.1</td>
<td>61.9</td>
<td>95.7</td>
<td>142.0</td>
<td>35.4</td>
<td>8.2</td>
<td>175.9</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>Potelleigo</td>
<td>5.8</td>
<td>12.5</td>
<td>19.9</td>
<td>28.4</td>
<td>8.2</td>
<td>2.4</td>
<td>32.5</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Libmeldy/Lenmeldy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1.1</td>
<td>1.1</td>
<td>4.5</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Nourianz</td>
<td>1.7</td>
<td>3.5</td>
<td>5.5</td>
<td>8.2</td>
<td>1.6</td>
<td>(0.1)</td>
<td>8.5</td>
<td>18%</td>
<td></td>
</tr>
<tr>
<td>Nesp</td>
<td>2.2</td>
<td>4.4</td>
<td>7.0</td>
<td>9.1</td>
<td>2.9</td>
<td>0.7</td>
<td>10.7</td>
<td>27%</td>
<td></td>
</tr>
<tr>
<td>Regpara</td>
<td>0.9</td>
<td>1.9</td>
<td>3.1</td>
<td>4.0</td>
<td>1.2</td>
<td>0.3</td>
<td>3.9</td>
<td>31%</td>
<td></td>
</tr>
<tr>
<td>Neulasta/Peglasta</td>
<td>1.3</td>
<td>2.8</td>
<td>4.5</td>
<td>5.7</td>
<td>1.1</td>
<td>(0.2)</td>
<td>4.7</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Gran</td>
<td>1.4</td>
<td>3.2</td>
<td>5.2</td>
<td>6.9</td>
<td>1.8</td>
<td>0.3</td>
<td>7.2</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>Technology out-licensing</td>
<td>9.2</td>
<td>18.4</td>
<td>30.1</td>
<td>41.9</td>
<td>12.1</td>
<td>2.9</td>
<td>46.3</td>
<td>26%</td>
<td></td>
</tr>
<tr>
<td>Of which, Benralizumab royalty</td>
<td>5.7</td>
<td>11.6</td>
<td>19.1</td>
<td>27.4</td>
<td>6.4</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.
* Revenue listed as “Technology out-licensing” represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compounds or the use of technology, etc.
* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).
### III. Revenue from Main Products

#### Unit: Billions of yen

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>Change amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Apr - Jun</td>
<td>Jul - Sep</td>
</tr>
<tr>
<td>Crysivita</td>
<td>2.3</td>
<td>2.5</td>
<td>2.6</td>
</tr>
<tr>
<td>Poteliego</td>
<td>0.4</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Nesp</td>
<td>0.8</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Darbepoetin Alfa Injection Syringe [KKF]</td>
<td>3.5</td>
<td>3.4</td>
<td>3.5</td>
</tr>
<tr>
<td>Duvroq</td>
<td>1.8</td>
<td>2.4</td>
<td>2.6</td>
</tr>
<tr>
<td>PHOZEVEL</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Regpara</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Orkedia</td>
<td>2.2</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Rocaltril</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Onglyza</td>
<td>1.1</td>
<td>1.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Coniel</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>G-Lasta</td>
<td>7.0</td>
<td>7.9</td>
<td>8.2</td>
</tr>
<tr>
<td>Fentos</td>
<td>0.7</td>
<td>0.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Rituximab BS [KHK]</td>
<td>2.2</td>
<td>2.3</td>
<td>2.2</td>
</tr>
<tr>
<td>Romiplate</td>
<td>2.7</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Allelock</td>
<td>1.9</td>
<td>1.2</td>
<td>1.0</td>
</tr>
<tr>
<td>Patanol</td>
<td>1.4</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Dovobet</td>
<td>1.8</td>
<td>2.1</td>
<td>1.8</td>
</tr>
<tr>
<td>Lumicef</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Nouriast</td>
<td>1.7</td>
<td>2.0</td>
<td>1.9</td>
</tr>
<tr>
<td>HARUROPI</td>
<td>0.9</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Depakene</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Crysivita</td>
<td>27.1</td>
<td>34.8</td>
<td>33.8</td>
</tr>
<tr>
<td>Poteliego</td>
<td>5.8</td>
<td>6.6</td>
<td>7.5</td>
</tr>
<tr>
<td>Libmeldy/Lenmeldy</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nouriast</td>
<td>1.7</td>
<td>1.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Nesp</td>
<td>2.2</td>
<td>2.2</td>
<td>2.6</td>
</tr>
<tr>
<td>Regpara</td>
<td>0.9</td>
<td>1.0</td>
<td>1.2</td>
</tr>
<tr>
<td>Neulasta/Peglasta</td>
<td>1.3</td>
<td>1.5</td>
<td>1.7</td>
</tr>
<tr>
<td>Gran</td>
<td>1.4</td>
<td>1.8</td>
<td>2.0</td>
</tr>
<tr>
<td>Technology out-licensing</td>
<td>9.2</td>
<td>9.2</td>
<td>11.8</td>
</tr>
<tr>
<td>Of which, Benralizumab royalty</td>
<td>5.7</td>
<td>5.9</td>
<td>7.5</td>
</tr>
</tbody>
</table>

* Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.

* Revenue listed as “Technology out-licensing” represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compounds or the use of technology, etc.

* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).
## III. Revenue from Main Products

### Revenue of global strategic products

**<Accumulative>**

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
<th>FY 2024 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td><strong>Crysvita</strong></td>
<td>29.4</td>
<td>66.7</td>
<td>103.1</td>
</tr>
<tr>
<td>Japan</td>
<td>2.3</td>
<td>4.8</td>
<td>7.4</td>
</tr>
<tr>
<td>North America</td>
<td>18.8</td>
<td>46.0</td>
<td>70.2</td>
</tr>
<tr>
<td>EMEA</td>
<td>8.0</td>
<td>15.3</td>
<td>24.5</td>
</tr>
<tr>
<td>APAC</td>
<td>0.3</td>
<td>0.6</td>
<td>1.1</td>
</tr>
</tbody>
</table>

**Japan** 2.3 4.8 7.4 10.5 2.5 0.2 12.9 19%

**North America** 18.8 46.0 70.2 105.2 22.8 4.0 175.9 20%

**EMEA** 8.0 15.3 24.5 35.1 11.9 3.9 88.4 22%

**APAC** 0.3 0.6 1.1 1.6 0.6 0.4 0.5 4%

| **Total of global strategic products** | 35.7 | 80.1 | 124.5 | 182.7 | 46.4 | 10.8 | 223.2 | 21% |

**<Quarterly>**

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2023 results</th>
<th>FY 2024 results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Apr - Jun</td>
</tr>
<tr>
<td><strong>Crysvita</strong></td>
<td>29.4</td>
<td>37.3</td>
</tr>
<tr>
<td>Japan</td>
<td>2.3</td>
<td>2.5</td>
</tr>
<tr>
<td>North America</td>
<td>18.8</td>
<td>27.2</td>
</tr>
<tr>
<td>EMEA</td>
<td>8.0</td>
<td>7.3</td>
</tr>
<tr>
<td>APAC</td>
<td>0.3</td>
<td>0.3</td>
</tr>
</tbody>
</table>

**Japan** 2.3 2.5 2.6 3.1 2.5 0.2

**North America** 18.8 27.2 24.1 35.0 22.8 4.0

**EMEA** 8.0 7.3 9.2 10.7 11.9 3.9

**APAC** 0.3 0.3 0.5 0.5 0.6 0.4

| **Total of global strategic products** | 35.7 | 44.4 | 44.3 | 58.3 | 46.4 | 10.8 |

* Revenue is classified based on consolidated revenue from regional control functions.
* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.
As of Mar 31, 2024

### IV. R&D pipeline

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Stage</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK8123 Injection</td>
<td>Anti-FGF23 Fully Human Antibody</td>
<td>X-linked Hypophosphatemia (XLH)</td>
<td>[In-House] Preparation underway for PhI as a global product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMG531 Romiplostim Injection</td>
<td>Thrombopoietin Receptor Agonist</td>
<td>Aplastic Anemia Previously Untreated with Immunosuppressive Therapy</td>
<td>[Agenon K-A] product name in Japan: Romiplate Area of clinical study: Asia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKK2845</td>
<td>Acute Myelogenous Leukemia</td>
<td>[In-House] Antibody-Drug Conjugate Preparation underway for PhI in Japan as a global product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTL-203</td>
<td>Hematopoietic Stem Cell (HSC) Gene Therapy</td>
<td>MPS-IH (Hurler Syndrome)</td>
<td>[In-House] Rare Pediatric Disease (RPD) and Fast Track designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and Europe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTL-201</td>
<td>Hematopoietic Stem Cell (HSC) Gene Therapy</td>
<td>MPS-IIBA (Sanfilippo Syndrome type A)</td>
<td>[In-House] Rare Pediatric Disease (RPD) designation (FDA) Area of clinical study: UK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4083/AMG 451 Recatinlimab Injection</td>
<td>Anti-OX40 Fully Human Antibody</td>
<td>Atopic Dermatitis</td>
<td>[In-House] POTELIGENT Fully human antibody production technology Collaboration agreement with Agenon for the development of KHK4083/AMG 451 in all the countries except for Japan. Clinical study is being conducted in JP, NA, EU, UK, Middle East, Asia, Oseania, and other regions as a global product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prurigo Nudulans</td>
<td>Preparation underway for PhII as a global product</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>Preparation underway for PhI as a global product</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4951 Tivozanib Ophthalmic</td>
<td>VEGF Receptor Tyrosine Kinase Inhibitor</td>
<td>Diabetic Macular Edema</td>
<td>[In-House] Clinical study is being conducted in JP, NA, Asia, and Oseania as a global product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neovascular Age-Related Macular Degeneration</td>
<td>Clinical study is being conducted in JP, NA, Asia, and Oseania as a global product</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTL-200 Injection</td>
<td>EGFR-TfR1Bispecific Antibody</td>
<td>Solid Tumor</td>
<td>[In-House] REGULGENT Fully human antibody production technology As a global product, clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKK2269 Injection</td>
<td>EpCAM-CD40Bispecific Antibody</td>
<td>Solid Tumor</td>
<td>[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKK2267 Injection</td>
<td>Anti-PTPRS Humanized Antibody</td>
<td>Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus</td>
<td>[SBI Biotech] POTELIGENT Clinical study is being conducted in JP and Asia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Since the development of KW-3357 for disseminated intravascular coagulation, congenital antithrombin deficiency was discontinued in Europe and UK, the relevant information was deleted from this table.

### Major Applications and Approvals

<table>
<thead>
<tr>
<th>Code Name, Generic Name, Product Name</th>
<th>Indication</th>
<th>Application/Under Review</th>
<th>Countries/Regions Received Approval in 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4827(brodalumab, Product name in Japan and Asia: Lumicef)</td>
<td>Systemic Sclerosis</td>
<td>JP</td>
<td>–</td>
</tr>
<tr>
<td>KHK7580(Evocalcel, Product name in Japan: Orkeda)</td>
<td>Secondary Hyperparathyroidism</td>
<td>CN</td>
<td>TW</td>
</tr>
</tbody>
</table>